A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10\^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).

Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.